MEASUREMENT OF ADVANCED GLYCATION END-PRODUCTS 203 (10) M. J. Noordz ij, D. J. Mulder, P. H. Oomen, T. Brouwer, J. Jager, M. Castro Cabezas, J. D. Lefrandt, and A. J. Smit, Skin autofl uorescence and risk of micro- and macrovascular complications in patients with type 2 diabetes mellitus—A multi-centre study, Diabet. Med., 29, 1556–1561 (2012). (11) R. Meerwaldt , H. L. Lutgers, T. P. Links, R. Graaff, J. W. Baynes, R. O. Gans, and A. J. Smit, Skin autofl uorescence is a strong predictor of cardiac mortality in diabetes, Diabetes Care, 30, 107–112 (2007). (12) J. W. Hartog , A. P. de Vries, H. L. Lutgers, R. Meerwaldt, R. M. Huisman, W. J. van Son, P. E. de Jong, and A. J. Smit, Accumulation of advanced glycation end products, measured as skin autofl uorescence in renal disease, Ann. NY Acad. Sci., 1043, 299–307 (2005). (13) R. Meerwaldt , T. P. Links, R. Graaff, K. Hoogenberg, J. D. Lefrandt, J. W. Baynes, R. O. Gans, and A. J. Smit, Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy, Diabetologia, 48, 1637–1644 (2005). (14) N. J. McInty re, R. J. Fluck, C. W. McIntyre, and M. W. Taal, Skin autofl uorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3, Clin. J. Am. Soc. Nephrol., 6, 2356–2363 (2011). (15) A. Smit and E. Gerrits. Skin autofl uorescence as a measure of advanced glycation endproduct deposition: A novel risk marker in chronic kidney disease, Curr. Opin. Nephrol. Hypertens., 19, 527–533 (2010). (16) H. L. Nienhu is, K. de Leeuw, J. Bijzet, A. Smit, C. G. Schalkwijk, R. Graaff, C. G. Kallenberg, and M. Bijl, Skin autofl uorescence is increased in systemic lupus erythematosus but is not refl ected by elevated plasma levels of advanced glycation endproducts, Rheumatology, 47, 1554–1558 (2008). (17) Y. Ohnuki, R . Nagano, S. Takizawa, S. Takagi, and T. Miyata, Advanced glycation end products in patients with cerebral infarction, Intern. Med., 48, 587–591 (2009). (18) Y. Kouidrat, A. Amad, M. Arai, M. Miyashita, J. D. Lalau, G. Loas, and M. Itokawa, Advanced glyca- tion end products and schizophrenia: A systematic review, J. Psychiat. Res., 66, 112–117 (2015). (19) L. C. de Vos , M. J. Noordzij, D. J. Mulder, A. J. Smit, H. L. Lutgers, R. P. Dullaart, P. W. Kamphuisen, C. J. Zeebregts, and J. D. Lefrandt, Skin autofl uorescence as a measure of advanced glycation end prod- ucts deposition is elevated in peripheral artery disease, Arterioscler. Thromb. Vasc. Biol., 33, 131–138 (2013). (20) L. C. de Vos, D. J. Mulder, A. J. Smit, R. P. Dullaart, N. Kleefstra, W. M. Lijfering, P. W. Kamphuisen, C. J. Zeebregts, and J. D. Lefrandt, Skin autofl uorescence is associated with 5-year mortality and cardiovascular events in patients with peripheral artery disease, Arterioscler. Thromb. Vasc. Biol., 34, 933–938 (2014). (21) S. Willemsen, J. W. Hartog, Y. M. Hummel, J. L. Posma, L. M. van Wijk, D. J. van Veldhuisen, and A. A. Voors, Effects of alagebrium, an advanced glycation endproduct breaker, in patients with chronic heart failure: Study design and baseline characteristics of the BENEFICIAL trial, Eur. J. Heart Fail., 12, 294–300 (2010). (22) M. Koetsier, H. L. Lutgers, C. de Jonge, T. P. Links, A. J. Smit, and R. Graaff, Reference values of skin autofl uorescence, Diabetes Technol. Ther., 12, 399–403 (2010). (23) K. Simon-Klenovics, R. Kollárová, J. Hodosy, P. Celec, and K. Sebeková, Reference values of skin auto- fl uorescence as an estimation of tissue accumulation of advanced glycation end products in a general Slovak population, Diabet. Med., 31, 581–585 (2014). (24) K. Nomoto, M. Yagi, S. Arita, U. Hamada, and Y. Yonei, A survey of fl uorescence derived from ad- vanced glycation end products in the skin of Japanese: Differences with age and measurement location, Anti-Aging Med., 9, 119–124 (2012). (25) X. Yue, H. Hu, M. Koetsier, R. Graaff, and C. Han, Reference values for the Chinese population of skin autofl uorescence as a marker of advanced glycation end products accumulated in tissue, Diabet. Med, 28, 818–823 (2013). (26) M. S. Ahmad, Z. A. Damanhouri, T. Kimhofer, H. H. Mosli, and E. Holmes, A new gender-specifi c model for skin autofl uorescence risk stratifi cation, Sci. Rep., 5, 10198 (2015). (27) R. Na, I. M. Stender, M. Henriksen, and H. C. Wulf, Autofl uorescence of human skin is age-related after correction for skin pigmentation and redness, J. Invest. Dermatol., 116, 536–540 (2001). (28) H. Masaki, Y. Okano, and H. Sakurai, Generation of active oxygen species from advanced glycation end-products (AGEs) during ultraviolet light A (UVA) irradiation and a possible mechanism for cell damaging, Biochem. Biophys. Acta, 1428, 45–56 (1999). (29) G. T. Wondrak, M. K. Jacobson, and E. L. Jacobson, Endogenous UVA-photosensitizers: Mediators of skin photodamage and novel targets for skin photoprotection, Photochem. Photobiol. Sci., 5, 215–237 (2005).

JOURNAL OF COSMETIC SCIENCE 204 (30) N. Kollias, R. Gillies, M. Moran, I. E. Kochevar, and R. R. Anderson, Endogenous skin fl uorescence includes bands that may serve as quantitative markers of aging and photoaging, J. Invest. Dermatol., 111, 776–780 (1998). (31) C. Jeanmaire, L. Danoux, G. Pauly. Glycation during human dermal intrinsic and actinic ageing: An in vivo and in vitro model study, Br. J. Dermatol., 145, 10–18 (2001). (32) S. J. Hoonhorst, A. T. Lo Tam Loi, J. E. Hartman, E. D. Telenga, M. van den Berge, L. Koenderman, J. W. Lammers, H. M. Boezen, D. S. Postma, and N. H. Ten Hacken, Advanced glycation end products in the skin are enhanced in COPD, Metabolism, 63, 1149–1156 (2014). (33) K. Nomoto, M. Yagi, S. Arita, M. Ogura, and Y. Yonei, Skin accumulation of advanced glycation end products and lifestyle behaviors in Japanese, Anti-Aging Med., 9, 165–173 (2012). (34) M. Fu, K. Wells-Knecht, J. Blackledge, T. J. Lyons, S. R. Thorpe, and J. W. Baynes, Glycation, gly- coxidation, and cross-linking of collagen by glucose: Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction, Diabetes, 43, 676–683 (1994). (35) J. V. Hunt, R. T. Dean, and S. Wolff, Hydroxyl radical production and autoxidative glycosylation - Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing, Biochem. J., 256, 205–212 (1988). (36) G. Rhie, M. H. Shin, J. Y. Seo, W. W. Choi, K. H. Cho, K. H. Kim, K. C. Park, H. C. Eun, and J. H. Chung, Aging- and photoaging-dependent changes of enzymic and nonenzymic antioxidants in the epidermis and dermis of human skin in vivo, J. Invest. Dermatol., 117, 1212–1217 (2001). (37) D. Qu and Y. Park. Skin youthfulness index – A novel model correlating age with objectively measured visual parameters of facial skin, IFSCC Mag., 17(3), 9–16 (2014). Footnote: IRB review of the study. IRB review of the study: This was a skin assessment study conducted on volunteers using a medical device for diagnostic use that has been deemed of no signifi cant risk. As per the Food and Drug Administration Information Sheet Guidance “Signifi cant Risk and Nonsignifi cant Risk Medical Device Studies,” the following exemption for IRB approval applies to this study: …. diagnostic device studies (e.g., in vitro diagnostic studies) are exempt from the requirements of 21 CFR Part 812 under certain circumstances. The study is exempt as long as the sponsor complies with the requirements at 21 CFR 809.10(c) for labeling, and if the testing: (i) is noninvasive (ii) does not require an invasive sampling procedure that presents signifi cant risk (iii) does not by design or intention introduce energy into a subject and (iv) is not used as a diagnostic procedure without confi rmation of the diag- nosis by another, medically established diagnostic product or procedure. 21 CFR 812.2(c)(3). Therefore, while we followed guidelines of good clinical practices including informed consent and appropriate legal oversight, we did not seek an IRB approval as per the previ- ously mentioned exemption.